ClinicalTrials.gg
Status unknownNCT04380532COVID-19Updated May 27, 2020

Tableted COVID-19 Therapeutic Vaccine

A Phase 1/2 interventional study of V-SARS in Covid19, sponsored by Immunitor LLC. Status unknown at 2 sites in 2 countries. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-05-27.

Sponsored by Immunitor LLC · Phase 1/2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified May 2020), so the status shown — last known as Active, not recruiting — may be out of date.
Phase
Phase 1/2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Safety and immunogenicity one-month study in healthy individuals administered once-daily pill of therapeutic vaccine made from heat-inactivated plasma from donors with COVID-19. Healthy, at least 20, volunteers will be monitored for signs of adverse events. Their PBMC will be collected at baseline and one month later to analyze which type of immune response vaccine has induced.

Read the detailed description

Experimental batch of tableted thermostable vaccine obtained from pooled plasma of COVID-19 patients is produced. The goal of this trial is test safety and immunogenicity of once-per-day day administered orally to volunteers for 15 days. Baseline and post-treatment standard safety parameters will be compared. Blood samples from volunteers will be monitored and immunogenicity lab assays will be undertaken to characterize immune response.

02

Conditions studied

  • Covid19

Keywords

  • COVID-19
  • SARS-CoV-2
  • coronavirus
  • respiratory disease
  • SARS
  • ARDS
  • pneumonia
  • pandemic
03

In context

COVID-19

7,990 studies on the registry are indexed under COVID-19; 466 are open to participants now.

This study's planned enrollment of 20 is below the median of 102 across 4,364 interventional studies indexed under COVID-19.

Browse COVID-19 studies →

Lead sponsor

Immunitor LLC is the lead sponsor of 14 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed cases of Covid-19 (all by RT-PCR from same laboratory)
  • Mild to severe clinical presentation (identified at the time of admission to ward by National Early Warning Score NEWS-2; mild 0-4; severe 5-6)

Exclusion criteria

Exclusion Criteria:

  • Unable to take oral medication,
  • Known comorbid condition like hypertension, cardiovascular disease, diabetes mellites, asthma, , cerebrovascular disorder, of any type, pregnancy,
  • less than 18
  • Smoking history (more than one pack per day)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    V-SARS recipients

    Single arm having at least 20 volunteers administered once-per-day pill of V-SARS

    Biological: V-SARS

Interventions

  • BiologicalV-SARS

    Therapeutic vaccine formulated as a pill derived from heat-inactivated plasma from COVID-19 patients administered once-per-day to at least 20 healthy volunters for at least one month

06

What researchers measure

Primary outcomes

  1. Effect on CBC as per CTCAE v4.0

    Routine laboratory complete blood cell count at pre- and post-treatment periods by automated CBC counter Routine laboratory complete blood count Routine clinical laboratory CBC parameters at pre- and post-treatment periods

    Time frame: 15 Days

  2. Effect on biochemistry parameters as per CTCAE v4.0

    Routine clinical laboratory blood biochemistry parameters at pre- and post-treatment periods by automated biochemistry analyzer

    Time frame: 15 Days

Secondary outcomes

  1. Lack of adverse events as per CTCAE v4.0

    Clinical well-being assessed by CTCAE v4.0

    Time frame: 15 days

07

Study locations

2 sites
  • Immunitor Inc
    Vancouver, BC - British Columbia V6K 2G8, Canada
  • Aldar Bourinbayar
    Ulaanbaatar, BZD, 3-khoroo 13381, Mongolia
08

References and documents

Publications

  • Silin DS, Lyubomska OV, Jirathitikal V, Bourinbaiar AS. Oral vaccination: where we are? Expert Opin Drug Deliv. 2007 Jul;4(4):323-40. doi: 10.1517/17425247.4.4.323. PubMed 17683247 ↗

Individual participant data

Plan to share: Yes — Free dissemination of published data

Supporting information: Study protocol

Time frame: when become public

Access criteria: non-confidential data

Data sharing details ↗ · immunitor.com

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 27, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04380532
Lead sponsor
Immunitor LLC
Collaborators
Immunitor Inc.
Responsible party
Sponsor
First posted
May 8, 2020
Start date
May 15, 2020
Primary completion
May 15, 2021 (estimated)
Completion
Jun 15, 2021 (estimated)
Last update
May 27, 2020

Study contacts

Aldar Bourinbayar, MD/PhD
principal investigator · Immunitor LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion